Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIT | P10721 | 2/20 | 0.43 |
| ▸ | ACACB | O00763 | 4/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.39 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.39 |
| ▸ | NAMPT | P43490 | 3/20 | 0.39 |
| ▸ | JAK3 | P52333 | 2/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25228458 | 0.89 | KIT (0.44) | KITACACBGPR119CYP11B2NAMPT | |
| SCHEMBL25272218 | 0.88 | KIT (0.45) | KITACACBGPR119CYP11B2NAMPT | |
| SCHEMBL25270429 | 0.83 | KIT (0.45) | KITACACBGPR119CYP11B2NAMPT | |
| SCHEMBL25276952 | 0.81 | KIT (0.42) | KITACACBGPR119CYP11B2NAMPT | |
| SCHEMBL30456119 | 0.78 | KIT (0.49) | KITGPR119CYP11B2NAMPTJAK3 | |
| SCHEMBL30406162 | 0.73 | KIT (0.52) | KITCYP11B2JAK3 | |
| SCHEMBL30456403 | 0.73 | ACACB (0.41) | KITACACBGPR119CYP11B2NAMPT | |
| SCHEMBL30680157 | 0.73 | MAP4K4 (0.47) | KITACACBGPR119CYP11B2JAK3 | |
| SCHEMBL24772750 | 0.73 | MAP4K4 (0.47) | KITACACBGPR119CYP11B2JAK3 | |
| SCHEMBL25275253 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250163061-A1 | INHIBITORS OF MENIN-MLL INTERACTION | BALA THERAPEUTICS, INC. | 2025-05-22 | — | — | US | disclosed |
| US-20250066358-A1 | Inhibitors of Menin-MLL Interaction | BALA THERAPEUTICS, INC. | 2025-02-27 | — | — | US | disclosed |
| EP-4444313-A1 | INHIBITORS OF MENIN-MLL INTERACTION | Bala Therapeutics, Inc. (US) | 2024-10-16 | — | — | EP | disclosed |
| WO-2023107687-A1 | INHIBITORS OF MENIN-MLL INTERACTION | BALA THERAPEUTICS, INC. (US) | 2023-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250163061-A1 | INHIBITORS OF MENIN-MLL INTERACTION | MLLT1, MEN1, BMI1 | KIT 1067/4885ACACB 1663/4885GPR119 2874/4885 |
| US-20250066358-A1 | Inhibitors of Menin-MLL Interaction | MLLT1, MEN1, BMI1 | KIT 1067/4885ACACB 1663/4885GPR119 2874/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.